Factor v Leiden and FII 20210 testing in thromboembolic disorders

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue SUPPL. 1, 2010, Pages

  Pajič, Tadej ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Factor V Leiden; FII 20210; quantitative real time PCR; thromboembolic disorders

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; CARDIOVASCULAR RISK; GENE MUTATION; GENOTYPE; HUMAN; LABORATORY DIAGNOSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; CLINICAL CHEMISTRY TESTS; FACTOR V; HUMANS; HYDROLYSIS; MUTATION; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION; PROTHROMBIN; THROMBOEMBOLISM;

EID: 79251624495     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.372     Document Type: Article

References (82)

1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86: 452-63.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-93.
3. Rosendaal FR. Thrombosis in the young: Epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78:1-6.
4. Zoller B, Garcia de Frutos P, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999;84: 59-70.
5. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.
6. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008;112:19-27.
7. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
8. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
9. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-93.
10. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
11. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22. (Pubitemid 24058953)
12. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-400.
13. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994;83:3120-5.
14. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994;343:1535-6.
15. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8. (Pubitemid 24180052)
16. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
17. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995;270:4053-7.
18. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995;270:20794-800.
19. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994;269:18735-8.
20. Dahlback B. Activated protein C resistance and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999;25:273-89.
21. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361-2.
22. Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997;77:332-5.
23. Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994;344:1709.
24. Trossaert M, Conard J, Horellou MH, Elalamy I, Samama MM. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996;75:521-2.
25. Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ, et al. Technical standards and guidelines: Venous thromboembolism (Factor V Leiden and prothrombin 20210G )A testing): A disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med 2005;7:444-53.
26. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-7.
27. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: A new mutation (Arg306- > Thr) associated with resistance to activated protein C. Blood 1998;91: 1140-4.
28. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998;91:1135-9.
29. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
30. Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: Background and mechanisms. Thromb Haemost 2007;98:530-42.
31. Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor VLeiden mutation in four distinct American ethnic populations. Am J Med Genet 1997;73:334-6.
32. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of Factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305-7.
33. Alfirevic Z, Simundic AM, Nikolac N, Sobocan N, Alfirevic I, Stefanovic M, et al. Frequency of factor II G20210A, Factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case-control study. Biochemia Medica 2010;20:229-35.
34. Bedencic M, Bozic M, Peternel P, Stegnar M. Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia. Pathophysiol Haemost Thromb 2008;36:58-63.
35. Meglic L, Stegnar M, Milanez T, Bozic M, Peterlin B, Peternel P. Factor V Leiden, prothrombin 20210G - > A, methylenetetrahydrofolate reductase 677C -) T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism. Eur J Obstet Gynecol Reprod Biol 2003;111:157-63.
36. Zoller B, Hillarp A, Berntorp E, Dahlback B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 1997;48: 45-58. (Pubitemid 27101813)
37. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88: 3698-703.
38. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, et al. Increased efficiency of mRNA 39 end formation: A new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001;28:389-92.
39. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000;111:1223-9.
40. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism- pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86: 809-16.
41. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997;78: 1426-9.
42. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
43. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998;80: 49-51.
44. Tosetto A, Frezzato M, Rodeghiero F. Family history and inherited thrombophilia. Br J Haematol 1995;89:227-8.
45. Howard TE, Marusa M, Boisza J, Young A, Sequeira J, Channell C, et al. The prothrombin gene 3'-untranslated region mutation is frequently associated with Factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency. Blood 1998;91:1092.
46. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both Factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-6.
47. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene. Br J Haematol 1997;98:907-9.
48. Emadi A, Crim MT, Brotman DJ, Necochea AJ, Samal L, Wilson LM, et al. Analytic validity of genetic tests to identify Factor V Leiden and prothrombin G20210A. Am J Hematol 2010;85:264-70.
49. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344:1162-3.
50. Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73:732-3.
51. de Ronde H, Bertina RM. Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the Factor V Leiden mutation. Blood Coagul Fibrinol 1999;10:7-17.
52. Dahlback B. Resistance to activated protein C as risk factor for thrombosis: Molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997;34:217-34.
53. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997;43: 1678-83.
54. Simundic AM, Topic E, Stefanovic M. Detection of Factor V Leiden by PCR-SSCP using GMA precast Elchrom scientific gels. Clin Appl Thromb Hemost 2003;9:227-31.
55. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY) 1992;10:413-7.
56. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: Real-time monitoring of DNA amplification reactions. Biotechnology (NY) 1993;11:1026-30.
57. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997;22:130-1, 134-8.
58. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
59. Bonetta L. Prime time for real-time PCR. Nat Methods 2005;2:305-312.
60. Wittwer CT, Herrmann MG, Gundry CN, Elenitoba-Johnson KS. Real-time multiplex PCR assays. Methods 2001;25: 430-42.
61. Elenitoba-Johnson KS, Bohling SD, Wittwer CT, King TC. Multiplex PCR by multicolor fluorimetry and fluorescence melting curve analysis. Nat Med 2001;7:249-53.
62. Hertzberg M, Neville S, Favaloro E, McDonald D. External quality assurance of DNA testing for thrombophilia mutations. Am J Clin Pathol 2005;123:189-93.
63. Cooper PC, Rezende SM. An overview of methods for detection of Factor V Leiden and the prothrombin G20210A mutations. Int J Lab Hematol 2007;29:153-62.
64. Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 1999;17:804-7.
65. Kutyavin IV. New approach to real-time nucleic acids detection: Folding polymerase chain reaction amplicons into a secondary structure to improve cleavage of Forster resonance energy transfer probes in 59-nuclease assays. Nucleic Acids Res 2010;38:e29.
66. Lyondagger E, Millsondagger A, Phan T, Wittwer CT. Detection and identification of base alterations within the region of Factor V Leiden by fluorescent melting curves. Mol Diagn 1998;3:203-9.
67. Package Insert, Factor V Leiden Kit. Roche Diagnostics, Mannheim, Germany.
68. Package Insert, Factor II (Prothrombin) G201210A Kit. Roche Diagnostics, Mannheim, Germany.
69. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 1995;4:357-62.
70. Sevall JS. Rapid allelic discrimination from real-time DNA amplification. Methods 2001;25:452-5.
71. Genotyping Experiments, in Applied Biosystems Real-Time PCR Systems Reagent Guide, Applied Biosystems, 2010: 3-15pp.
72. Yao Y, Nellaker C, Karlsson H. Evaluation of minor groove binding probe and Taqman probe PCR assays: Influence of mismatches and template complexity on quantification. Mol Cell Probe 2006;20:311-6.
73. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques 2005;39:75-85.
74. Package Insert, FACTOR V Q-PCR Alert Kit. Nanogen Advanced Diagnostics S.r.L., Torino, Italy: SCH m- RTSD01VP-en 14/07/06.
75. Package Insert, FACTOR II Q-PCR Alert Kit. Nanogen Advanced Diagnostics S.r.L., Torino, Italy: SCH m- RTSD01IIM-en 14/07/06.
76. Bianchi M, Emanuele E, Davin A, Gagliardi S, Cova E, Meli V, et al. Comparison of three methods for genotyping of prothrombotic polymorphisms. Clin Exp Med 2010;10:269-72.
77. Ng CT, Gilchrist CA, Lane A, Roy S, Haque R, Houpt ER. Multiplex real-time PCR assay using Scorpion probes and DNA capture for genotype-specific detection of Giardia lamblia on fecal samples. J Clin Microbiol 2005;43:1256-60.
78. Xia QF, Xu SX, Wang DS, Wen YA, Qin X, Qian SY, et al. Development of a novel quantitative real-time assay using duplex Scorpion primer for detection of Chlamydia trachomatis. Exp Mol Pathol 2007;83:119-24.
79. Thelwell N, Millington S, Solinas A, Booth J, Brown T. Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 2000;28:3752-61.
80. Burucoa C, Garnier M, Silvain C, Fauchere JL. Quadruplex real-time PCR assay using allele-specific Scorpion primers for detection of mutations conferring clarithromycin resistance to Helicobacter pylori. J Clin Microbiol 2008;46:2320-6.
81. Elnifro EM, Ashshi AM, Cooper RJ, Klapper PE. Multiplex PCR: Optimization and application in diagnostic virology. Clin Microbiol Rev 2000;13:559-70.
82. Package Insert, Xpert HemosIL FII&FV Cepheid, Sunnyvale, California, USA and Instrumentation Laboratory, Bedford, Massachusetts, USA 300-8501 Rev. B, May 2010.